Octreotide-modified nanomedicine for cancer treatment or cancer palliative care
    2.
    发明授权
    Octreotide-modified nanomedicine for cancer treatment or cancer palliative care 有权
    用于癌症治疗或癌症姑息治疗的奥曲肽修饰的纳米医药

    公开(公告)号:US09289463B2

    公开(公告)日:2016-03-22

    申请号:US13823821

    申请日:2011-02-23

    摘要: The present invention relates to a medical composition for treatment, palliative care or prevention of cancer, such as medullary thyroid carcinoma. Specifically, the invention relates to a medical composition for treatment, palliative care or prevention of medullary thyroid carcinoma, which comprises liposomes modified with octreotide.

    摘要翻译: 本发明涉及用于治疗,姑息治疗或预防癌症的药物组合物,例如甲状腺髓样癌。 具体地,本发明涉及用于治疗,姑息治疗或预防甲状腺髓样癌的医药组合物,其包括用奥曲肽修饰的脂质体。

    OCTREOTIDE-MODIFIED NANOMEDICINE FOR CANCER TREATMENT OR CANCER PALLIATIVE CARE
    3.
    发明申请
    OCTREOTIDE-MODIFIED NANOMEDICINE FOR CANCER TREATMENT OR CANCER PALLIATIVE CARE 有权
    用于癌症治疗或癌症治疗的OCTREOTID-MODIFIED NANOMEDICINE

    公开(公告)号:US20130171243A1

    公开(公告)日:2013-07-04

    申请号:US13823821

    申请日:2011-02-23

    IPC分类号: A61K38/08 A61K31/4745

    摘要: The present invention relates to a medical composition for treatment, palliative care or prevention of cancer, such as medullary thyroid carcinoma. Specifically, the invention relates to a medical composition for treatment, palliative care or prevention of medullary thyroid carcinoma, which comprises liposomes modified with octreotide.

    摘要翻译: 本发明涉及用于治疗,姑息治疗或预防癌症的药物组合物,例如甲状腺髓样癌。 具体地,本发明涉及用于治疗,姑息治疗或预防甲状腺髓样癌的医药组合物,其包括用奥曲肽修饰的脂质体。